Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the Spanish Society of Clinical Pharmacology

Frontiers in Pharmacology

Volumn 3 JAN, Issue , 2012, Pages

  Agúndez, José A G ^a,b   del Barrio, Jaime ^c   Stephens, Camilla ^d,e   Farré, Magí ^h   Andrade, Raúl J ^f,g   Badimon, Lina ^d,e   García Martín, Elena ^a,b   Vilahur, Gemma ^d,e   Lucena, M Isabel ^f,g  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b Red de Investigación de Reacciones Adversas a Alergenos y Fármacos   (Spain)

^c Roche Institute   (Spain)

^d Institut Català de Ciències Cardiovasculars   (Spain)

^e CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^g INSTITUTO DE SALUD CARLOS III   (Spain)

^h UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Biomarkers; Drug safety; Drug induced liver injury; Pharmacogenomics

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; DRUG METABOLIZING ENZYME; MERCAPTOPURINE; PHENYTOIN; THIOPURINE METHYLTRANSFERASE;

ARTICLE; CLINICAL PRACTICE; DISEASE PREDISPOSITION; DNA POLYMORPHISM; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG RECALL; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; GENE; GENETIC ALGORITHM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; LIFESTYLE; LIVER TOXICITY; MAINTENANCE DRUG DOSE; MEDICAL SOCIETY; NONHUMAN; PATHOGENESIS; PATIENT CARE; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PROTEIN ANALYSIS; TOXIC HEPATITIS; TPMT GENE; TREATMENT RESPONSE; TREND STUDY;

EID: 84865982625     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00002     Document Type: Article

References (32)

1. Agundez, J. A., Garcia-Martin, E., and Martinez, C. (2009). Genetically based impairment in CYP2C8and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin. Drug Metab. Toxicol. 5, 607-620.
2. Agundez, J. A., Golka, K., Martinez, C., Selinski, S., Blaszkewicz, M., and Garcia-Martin, E. (2008). Unraveling ambiguous NAT2 genotyping data. Clin. Chem. 54, 1390-1394.
3. Agundez, J. A., Lucena, M. I., Martinez, C., Andrade, R. J., Blanca, M., Ayuso, P., and Garcia-Martin, E. (2011). Assessment of nonsteroidal antiinflammatory drug-induced hepatotoxicity. Expert Opin. Drug Metab. Toxicol. 7, 817-828.
4. Andrade, R. J., Agundez, J. A., Lucena, M. I., Martinez, C., Cueto, R., and Garcia-Martin, E. (2009). Pharmacogenomics in drug induced liver injury. Curr.DrugMetab.10, 956-970.
5. Biomarkers Definitions Working Group. (2001). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95.
6. Daly, A. K., Donaldson, P. T., Bhatnagar, P., Shen, Y., Pe'er, I., Floratos, A., Daly, M. J., Goldstein, D. B., John, S., Nelson, M. R., Graham, J., Park, B. K., Dillon, J. F., Bernal, W., Cordell, H. J., Pirmohamed, M., Aithal, G. P., and Day, C. P. (2009). HLAB*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 41, 816-819.
7. Deverka, P. A., Doksum, T., and Carlson, R. J. (2007). Integrating molecular medicine into the US health-care system: opportunities, barriers, and policy challenges. Clin. Pharmacol. Ther. 82, 427-434.
8. European Medicines Agency. (2009). ICH guideline E16. Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions, EMA/CHMP/ICH/380636/2009. London: European Medicines Agency.
9. Food and Drug Administration. (2011). Table of Pharmacogenomic Biomarkers in Drug Labels. Available at: http://www.fda.gov/ drugs/scienceresearch/researchareas/ pharmacogenetics/ucm083378.htm
10. Ford, L., Kampanis, P., and Berg, J. (2009). Thiopurine S-methyltransferase genotype-phenotype concordance: used as a quality assurance tool to help control the phenotype assay. Ann. Clin. Biochem. 46, 152-154.
11. Garcia-Closas, M., Hein, D. W., Silverman, D., Malats, N., Yeager, M., Jacobs, K., Doll, M. A., Figueroa, J. D., Baris, D., Schwenn, M., Kogevinas, M., Johnson, A., Chatterjee, N., Moore, L. E., Moeller, T., Real, F. X., Chanock, S., and Rothman, N. (2011). A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background. Pharmacogenet. Genomics 21, 231-236.
12. Green, E. D., and Guyer, M. S. (2011). Charting a course for genomic medicine from base pairs to bedside. Nature 470, 204-213.
13. Groenen, P. M. (2011). Conference scene: four decades of modern pharmacogenomics: from promise to clinical utility. Pharmacogenomics 12, 1249-1252.
14. Haga, S. B., and Burke, W. (2008). Pharmacogenetic testing: not as simple as it seems. Genet. Med. 10, 391-395.
15. Institute of Medicine. (2011). Perspectives on Biomarker and Surrogate Endpoint Evaluation: Discussion Forum Summary. Washington, DC: The National Academies Press.
16. Johnson, J. A., Gong, L., Whirl-Carrillo, M., Gage, B. F., Scott, S. A., Stein, C. M., Anderson, J. L., Kimmel, S. E., Lee, M. T., Pirmohamed, M., Wadelius, M., Klein, T. E., and Altman, R. B. (2011). Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90, 625-629.
17. Lesko, L. J., Zineh, I., and Huang, S. M. (2010). What is clinical utility and why should we care? Clin. Pharmacol. Ther. 88, 729-733.
18. Lucena, M. I., Andrade, R. J., Martinez, C., Ulzurrun, E., Garcia-Martin, E., Borraz, Y., Fernandez, M. C., Romero-Gomez, M., Castiella, A., Planas, R., Costa, J., Anzola, S., and Agundez, J. A. (2008). Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 48, 588-596.
19. Lucena, M. I., Cohen, H., Hernandez, N., Bessone, F., Dacoll, C., Stephens, C., Borraz, Y., Ulzurrun, E., Bruguera, M., and Andrade, R. J. (2011a). Hepatotoxicity, a global problem with local features: toward the creation of a Pan-American hepatotoxicity network. Gastroenterol. Hepatol. 34, 361-368.
20. Lucena, M. I., Molokhia, M., Shen, Y., Urban, T. J., Aithal, G. P., Andrade, R. J., Day, C. P., Ruiz-Cabello, F., Donaldson, P. T., Stephens, C., Pirmohamed, M., Romero-Gomez, M., Navarro, J. M., Fontana, R. J., Miller, M., Groome, M., Bondon-Guitton, E., Conforti, A., Stricker, B. H., Carvajal,A.,Ibanez,L.,Yue,Q.Y.,Eichelbaum, M., Floratos,A., Pe'er, I., Daly, M. J., Goldstein, D. B., Dillon, J. F., Nelson, M. R., Watkins, P. B., and Daly, A. K. (2011b). Susceptibility to amoxicillin-clavulanateinduced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 141, 338-347.
21. Lucena, M. I., Garcia-Martin, E., Andrade, R. J., Martinez, C., Stephens, C., Ruiz, J. D., Ulzurrun, E., Fernandez, M. C., Romero-Gomez, M., Castiella, A., Planas, R., Duran, J. A., De Dios, A. M., Guarner, C., Soriano, G., Borraz, Y., and Agundez, J. A. (2010). Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. Hepatology 52, 303-312.
22. Matheis, K., Laurie, D., Andriamandroso, C., Arber, N., Badimon, L., Benain, X., Bendjama, K., Clavier, I., Colman, P., Firat, H., Goepfert, J., Hall, S., Joos, T., Kraus, S., Kretschmer, A., Merz, M., Padro, T., Planatscher, H., Rossi, A., Schneiderhan-Marra, N., Schuppe-Koistinen, I., Thomann, P., Vidal, J. M., and Molac, B. (2011). A generic operational strategy to qualify translational safety biomarkers. Drug Discov. Today 16, 600-608.
23. Pachkoria, K., Lucena, M. I., Ruiz-Cabello, F., Crespo, E., Cabello, M. R., and Andrade, R. J. (2007). Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). Br. J. Pharmacol. 150, 808-815.
24. Palmieri, O., Latiano, A., Bossa, F., Vecchi, M., D'Inca, R., Guagnozzi, D., Tonelli, F., Cucchiara, S., Valvano, M. R., Latiano, T., Andriulli, A., and Annese, V. (2007). Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines' toxicity and efficacy. Aliment. Pharmacol. Ther. 26, 737-745.
25. PHG Foundation. (2010). Public Health in an Era of Genome-Based and Personalised Medicine. Available at: http:// www.phgfoundation.org/file/6616
26. Relling, M. V., Altman, R. B., Goetz, M. P., and Evans, W. E. (2010). Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol. 11, 507-509.
27. Relling, M. V., Gardner, E. E., Sandborn, W. J., Schmiegelow, K., Pui, C. H., Yee, S. W., Stein, C. M., Carrillo, M., Evans, W. E., and Klein, T. E. (2011). Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89, 387-391.
28. Relling, M. V., and Klein, T. E. (2011). CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin. Pharmacol. Ther. 89, 464-467.
29. Scott, S. A., Sangkuhl, K., Gardner, E. E., Stein, C. M., Hulot, J. S., Johnson, J. A., Roden, D. M., Klein, T. E., and Shuldiner, A. R. (2011). Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin. Pharmacol. Ther. 90, 328-332.
30. Selinski, S., Blaszkewicz, M., Lehmann, M. L., Ovsiannikov, D., Moormann, O., Guballa, C., Kress, A., Tru, M. C., Gerullis, H., Otto, T., Barski, D., Niegisch, G., Albers, P., Frees, S., Brenner, W., Thuroff, J. W., Angeli-Greaves, M., Seidel, T., Roth, G., Dietrich, H., Ebbinghaus, R., Prager, H. M., Bolt, H. M., Falkenstein, M., Zimmermann, A., Klein, T., Reckwitz, T., Roemer, H. C., Lohlein, D., Weistenhofer, W., Schops, W., Hassan Rizvi, S. A., Aslam, M., Banfi, G., Romics, I., Steffens, M., Ekici, A. B., Winterpacht, A., Ickstadt, K., Schwender, H., Hengstler, J. G., and Golka, K. (2011). Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype. Pharmacogenet. Genomics 21, 673-678.
31. Singer, J. B., Lewitzky, S., Leroy, E., Yang, F., Zhao, X., Klickstein, L., Wright, T. M., Meyer, J., and Paulding, C. A. (2010). A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat. Genet. 42, 711-714.
32. Swen, J. J., Nijenhuis, M., De Boer, A., Grandia, L., Maitland-Van Der Zee, A. H., Mulder, H., Rongen, G. A., Van Schaik, R. H., Schalekamp, T., Touw, D. J., Van Der Weide, J., Wilffert, B., Deneer, V. H., and Guchelaar, H. J. (2011). Pharmacogenetics: from bench to byte an update of guidelines. Clin. Pharmacol. Ther. 89, 662-673.